Skip to main content
. 2020 May 7;13(4):777–784. doi: 10.1111/cts.12766

Figure 2.

Figure 2

The proposed precision dosing strategies are predicted to result in rivaroxaban average 24‐hour steady‐state area under the plasma concentration‐vs.‐time curve (AUC) values within ±20% of the target AUC for physiologically relevant ranges of creatinine clearance (CrCl) (15–250 ml/min) in adults. The target AUC (3,325.6 μg/h per liter) is represented by the solid gray horizontal line. The ±20% thresholds from the target AUC are demarcated by the dotted gray horizontal lines. The predicted AUC according to CrCl is displayed for the CrCl‐based dosing strategy. Predictions are for a 73‐kg, 73‐year‐old male subject.